%0 Journal Article
%A Guerreiro Stucklin, Ana S
%A Ryall, Scott
%A Fukuoka, Kohei
%A Zapotocky, Michal
%A Lassaletta, Alvaro
%A Li, Christopher
%A Bridge, Taylor
%A Kim, Byungjin
%A Arnoldo, Anthony
%A Kowalski, Paul E
%A Zhong, Yvonne
%A Johnson, Monique
%A Li, Claire
%A Ramani, Arun K
%A Siddaway, Robert
%A Nobre, Liana Figueiredo
%A de Antonellis, Pasqualino
%A Dunham, Christopher
%A Cheng, Sylvia
%A Boué, Daniel R
%A Finlay, Jonathan L
%A Coven, Scott L
%A de Prada, Inmaculada
%A Perez-Somarriba, Marta
%A Faria, Claudia C
%A Grotzer, Michael A
%A Rushing, Elisabeth
%A Sumerauer, David
%A Zamecnik, Josef
%A Krskova, Lenka
%A Garcia Ariza, Miguel
%A Cruz, Ofelia
%A Morales La Madrid, Andres
%A Solano, Palma
%A Terashima, Keita
%A Nakano, Yoshiko
%A Ichimura, Koichi
%A Nagane, Motoo
%A Sakamoto, Hiroaki
%A Gil-da-Costa, Maria Joao
%A Silva, Roberto
%A Johnston, Donna L
%A Michaud, Jean
%A Wilson, Bev
%A van Landeghem, Frank K H
%A Oviedo, Angelica
%A McNeely, P Daniel
%A Crooks, Bruce
%A Fried, Iris
%A Zhukova, Nataliya
%A Hansford, Jordan R
%A Nageswararao, Amulya
%A Garzia, Livia
%A Shago, Mary
%A Brudno, Michael
%A Irwin, Meredith S
%A Bartels, Ute
%A Ramaswamy, Vijay
%A Bouffet, Eric
%A Taylor, Michael D
%A Tabori, Uri
%A Hawkins, Cynthia
%T Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas.
%D 2019
%U http://hdl.handle.net/10668/14546
%X Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harbor RAS/MAPK pathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.
%~